KD 5170

HDAC inhibitor CAS# 940943-37-3

KD 5170

Catalog No. BCC2420----Order now to get a substantial discount!

Product Name & Size Price Stock
KD 5170: 5mg $104 In Stock
KD 5170: 10mg Please Inquire In Stock
KD 5170: 20mg Please Inquire Please Inquire
KD 5170: 50mg Please Inquire Please Inquire
KD 5170: 100mg Please Inquire Please Inquire
KD 5170: 200mg Please Inquire Please Inquire
KD 5170: 500mg Please Inquire Please Inquire
KD 5170: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of KD 5170

Number of papers citing our products

Chemical structure

KD 5170

3D structure

Chemical Properties of KD 5170

Cas No. 940943-37-3 SDF Download SDF
PubChem ID 17754557 Appearance Powder
Formula C20H25N3O5S2 M.Wt 451.56
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble in DMSO > 10 mM
Chemical Name S-[2-[6-[[4-[3-(dimethylamino)propoxy]phenyl]sulfonylamino]pyridin-3-yl]-2-oxoethyl] ethanethioate
SMILES CC(=O)SCC(=O)C1=CN=C(C=C1)NS(=O)(=O)C2=CC=C(C=C2)OCCCN(C)C
Standard InChIKey KXWBUKMWZKTHCV-UHFFFAOYSA-N
Standard InChI InChI=1S/C20H25N3O5S2/c1-15(24)29-14-19(25)16-5-10-20(21-13-16)22-30(26,27)18-8-6-17(7-9-18)28-12-4-11-23(2)3/h5-10,13H,4,11-12,14H2,1-3H3,(H,21,22)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of KD 5170

DescriptionClass I and II histone deacetylase (HDAC) inhibitor (IC50 = 0.045 μM; EC50 = 0.025 μM in HeLa screening and HeLa cell-based assays, respectively). Exhibits broad spectrum inhibition of HDAC classes I and II in assays using purified recombinant human isoforms. Displays less potent inhibition of HDAC2 (IC50 values are 0.014, 0.020, 0.026, 0.075 and 2.0 μM for HDAC6, HDAC1, HDAC4, HDAC3 and HDAC2 respectively). Displays cytotoxicity against numerous cell lines derived from human tumors. Orally available.

KD 5170 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

KD 5170 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of KD 5170

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.2145 mL 11.0727 mL 22.1455 mL 44.2909 mL 55.3636 mL
5 mM 0.4429 mL 2.2145 mL 4.4291 mL 8.8582 mL 11.0727 mL
10 mM 0.2215 mL 1.1073 mL 2.2145 mL 4.4291 mL 5.5364 mL
50 mM 0.0443 mL 0.2215 mL 0.4429 mL 0.8858 mL 1.1073 mL
100 mM 0.0221 mL 0.1107 mL 0.2215 mL 0.4429 mL 0.5536 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on KD 5170

KD 5170 is a novel inhibitor of histone deacetylase with IC50 value of 0.045 μM [1].

Histone deacetylases (HADC) are a series of enzymes that remove acetyl groups from an ε-N-acetyl lysine amino acid on a histone and make the histones to wrap the DNA more tightly, which prevent transcription.

KD 5170 is an inhibitor of histone deacetylase and inhibited recombinant HDAC enzymes with IC50 values of 0.020, 2.0, 0.075, 0.026, 0.014 μM for HADC1, HADC2, HADC3, HADC4 and HADC6, respectively. In HeLa cell, KD5170 resulted in histone hyperacetylation with an EC50 of 25 nM in a concentration-dependent way. In HCT-116 cells, KD 5170 induced p21WAF1 expression and histone H3 and a-tubulin acetylation [1][2]. In both HL-60 leukemia cells and HCT-116 colorectal cancer cells, KD5170 resulted in cell death in a concentration-dependent way [1].

In mice bearing HCT-116 xenograft tumors, KD 5170 significantly inhibited tumor growth [1]. In mice bearing H929 xenograft tumors, KD 5170 decreased tumor volume and significantly prolonged the mean time to endpoint. Also, the increase of histone acetylation was found in spleen and tumor tissues of the mice treated with KD 5170 [3].

References:
[1].  Hassig CA, Symons KT, Guo X, et al. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther, 2008, 7(5): 1054-1065.
[2].  Payne JE, Bonnefous C, Hassig CA, et al. Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor. Bioorg Med Chem Lett, 2008, 18(23): 6093-6096.
[3].  Feng R, Ma H, Hassig CA, et al. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol Cancer Ther, 2008, 7(6): 1494-1505.

Featured Products
New Products
 

References on KD 5170

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.[Pubmed:18566220]

Mol Cancer Ther. 2008 Jun;7(6):1494-505.

Histone deacetylase inhibitors have emerged as promising anticancer drugs. Using an unbiased ultrahigh throughput screening system, a novel mercaptoketone-based histone deacetylase inhibitor series was identified that was optimized to the lead compound, KD5170. KD5170 inhibited the proliferation of myeloma cell lines and the viability of CD138(+) primary myeloma cells by induction of apoptosis, accompanied by an increase of acetylation of histones and activation of caspase-3, caspase-8, and caspase-9. Treatment with KD5170 caused a loss of mitochondrial membrane potential resulting in release of apoptogenic factors such as cytochrome c, Smac, and apoptosis-inducing factor. Furthermore, KD5170 induced oxidative stress and oxidative DNA damage in myeloma cells as evidenced by the up-regulation of heme oxygenase-1 and H2A.X phosphorylation. Combination of KD5170 with proteasome inhibitor bortezomib or tumor necrosis factor-related apoptosis-inducing ligand synergistically enhanced the antimyeloma activity. We further found that resistance of myeloma cells to KD5170 was associated with activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway under treatment with KD5170. Pretreatment with the mitogen-activated protein kinase inhibitor U0126 restored sensitivity to KD5170, suggesting that the combination of KD5170 with U0126 could overcome drug resistance. Growth of myeloma tumor xenografts in KD5170-treated nude mice was significantly inhibited and survival was prolonged. Histone acetylation was increased in spleen and tumor tissues of animals treated with KD5170. Our data indicate that KD5170 has potent antimyeloma activity in vitro and in vivo, which is mediated by DNA damage and mitochondrial signaling and subsequent induction of apoptosis.

Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.[Pubmed:18954983]

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6093-6.

We report the identification of KD5170, a potent mercaptoketone-based Class I and II-histone deacetylase inhibitor that demonstrates broad spectrum cytotoxic activity against a range of human tumor-derived cell lines. KD5170 exhibits robust and sustained histone H3 hyperacetylation in HCT-116 xenograft tumors following single oral or i.v. dose and inhibition of tumor growth following chronic dosing.

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.[Pubmed:18483295]

Mol Cancer Ther. 2008 May;7(5):1054-65.

Histone deacetylase (HDAC) inhibitors have garnered significant attention as cancer drugs. These therapeutic agents have recently been clinically validated with the market approval of vorinostat (SAHA, Zolinza) for treatment of cutaneous T-cell lymphoma. Like vorinostat, most of the small-molecule HDAC inhibitors in clinical development are hydroxamic acids, whose inhibitory activity stems from their ability to coordinate the catalytic Zn2+ in the active site of HDACs. We sought to identify novel, nonhydroxamate-based HDAC inhibitors with potentially distinct pharmaceutical properties via an ultra-high throughput small molecule biochemical screen against the HDAC activity in a HeLa cell nuclear extract. An alpha-mercaptoketone series was identified and chemically optimized. The lead compound, KD5170, exhibits HDAC inhibitory activity with an IC50 of 0.045 micromol/L in the screening biochemical assay and an EC50 of 0.025 micromol/L in HeLa cell-based assays that monitor histone H3 acetylation. KD5170 also exhibits broad spectrum classes I and II HDAC inhibition in assays using purified recombinant human isoforms. KD5170 shows significant antiproliferative activity against a variety of human tumor cell lines, including the NCI-60 panel. Significant tumor growth inhibition was observed after p.o. dosing in human HCT-116 (colorectal cancer), NCI-H460 (non-small cell lung carcinoma), and PC-3 (prostate cancer) s.c. xenografts in nude mice. In addition, a significant increase in antitumor activity and time to end-point occurred when KD5170 was combined with docetaxel in xenografts of the PC-3 prostate cancer cell line. The biological and pharmaceutical profile of KD5170 supports its continued preclinical and clinical development as a broad spectrum anticancer agent.

Keywords:

KD 5170,940943-37-3,Natural Products,HDAC, buy KD 5170 , KD 5170 supplier , purchase KD 5170 , KD 5170 cost , KD 5170 manufacturer , order KD 5170 , high purity KD 5170

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: